REPL — Replimune Group, Inc. stock price, charts and financials

QT91Replimune Group, Inc.

Replimune Group, Inc. (NASDAQ: REPL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
11.91
+0.71+6.34%
OverviewShort InterestFilings
REPLQT91Replimune Group, Inc.·NASDAQ
11.91+6.34%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-Insider Own28.50%Shs Outstand83.96MPerf Week15.46%
Market Cap940.40MForward P/E-EPS next Y-1.70Insider Trans-0.47%Shs Float77.53MPerf Month-0.18%
Enterprise Value842.96MPEG0.55EPS next Q-Inst Own-Short Float30.51%Perf Quarter335.80%
Income-284.00MP/S0.00EPS this Y-Inst Trans-Short Ratio3.79Perf Half Y51.56%
Sales0.00P/B6.26EPS next Y27.41%ROA-94.45%Short Interest23.65MPerf YTD15.23%
Book/sh-P/C-EPS next 5Y-ROE-128.57%52W High13.29 -10.40%Perf Year48.34%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-114.79%52W Low1.60 646.67%Perf 3Y-45.95%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility21.48% 10.23%Perf 5Y-66.05%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-7.49%Oper. Margin0.00%ATR (14)1.44Perf 10Y-
Dividend Ex-Date-Quick Ratio4.79Sales Y/Y TTM-Profit Margin0.00%RSI (14)58.23Recom2.67
Dividend Gr. 3/5Y-Current Ratio4.79EPS Q/Q3.80%SMA2015.55%Beta0.86Target Price14.00
Payout0.00%Debt/Eq0.67Sales Q/Q-SMA5021.00%Rel Volume5.32Prev Close11.20
Employees465LT Debt/Eq0.64EarningsAug 06SMA20043.12%Avg Volume6.29MPrice11.91
IPO DateJul 20, 2018Option/ShortYes / YesEPS/Sales Surpr.-14.93% -Net Debt/EBITDA0.31Volume33,444,869Change6.34%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedWedbushNeutral$9.00 → $12
Jun-30-26ReiteratedBMO CapitalMarket Perform$11 → $16
Jun-30-26ReiteratedWedbushNeutral$18 → $9.00
Apr-13-26DowngradeCantor FitzgeraldOverweight → Neutral
Apr-13-26DowngradeWedbushOutperform → Neutral
Apr-13-26DowngradeJP MorganNeutral → Underweight
Apr-13-26DowngradeHC Wainwright & Co.Buy → Sell
Apr-13-26DowngradeJefferiesBuy → Hold
Apr-13-26DowngradeLeerink PartnersOutperform → Market Perform
Feb-05-26ReiteratedPiper SandlerOverweight$43 → $14
Latest News
Jul-31-26
Jul-31-2611:00AM
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firmglobenewswire.com
10:09AM
Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Votebenzinga.com
05:40AM
Replimune surges after FDA advisers back skin cancer drugreuters.com
Jul-30-26
Jul-30-2606:15PM
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanomaglobenewswire.com
05:48PM
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firmglobenewswire.com
05:27PM
A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug workswsj.com
05:10PM
US FDA panel backs Replimune skin cancer drug study datareuters.com
12:45PM
Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA ReviewSeekingAlpha
10:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLprnewswire.com
Jul-29-26
Jul-29-2608:00PM
REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraudglobenewswire.com
03:12PM
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firmbusinesswire.com
03:04PM
Replimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigationbusinesswire.com
Jul-28-26
Jul-28-2609:00PM
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced -- Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruzgurufocus.com
06:21PM
Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Documentglobenewswire.com
02:09PM
Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staffbenzinga.com
Company

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
FY 2018
3/31/2018
Total Revenue
000000000
Cost of Goods Sold Incl. D&A000054000
Gross Profit0000-5-4000
Selling, General and Administrative Excl. Other9900036211796
Research and Development2211891751278157392214
Other Operating Expense0736050010-3-3
Operating Income-320-262-235-177-121-83-56-31-19
Interest Expense987423200
Unusual Expense
—————————
Non-Operating Income (Expense)142326732500
Net Income Before Taxes-314-247-215-174-121-84-53-31-20
Income Taxes-1000-3-3000
Consolidated Net Income-314-247-216-174-118-81-53-31-20
Net Income From Continuing Operations-314-247-216-174-118-81-53-31-20
Net Income-314-247-216-174-118-81-53-31-20
EPS (Recurring)-3.38-3.07-3.24-2.99-2.26-1.75-1.54-1.33-0.64
EPS (Basic, Before Extraordinaries)-3.38-3.07-3.24-2.99-2.26-1.75-1.54-1.33-0.64
EPS (Diluted)-3.38-3.07-3.24-2.99-2.26-1.75-1.54-1.33-0.64
EBITDA-302-254-228-172-114-76-53-31-17
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding938167585246342331
Market Capitalization7117905471,0248831,403339350—
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$14.27$10.72$7.17$3.61$0.06● Close Price0.00K118.54K237.07K355.61K474.15KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale9.2412,000110,880180,962Jun 03
Astley-Sparke PhilipDirectorMay 18 '26Sale5.0817,65789,6981,412,414May 20
Patel SushilChief Executive OfficerMay 18 '26Sale5.0837,324189,606747,492May 20
Sarchi ChristopherChief Commercial OfficerMay 18 '26Sale5.088,62643,820192,962May 20
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale5.087,81239,685236,556May 20
Schwendenman AndrewChief Accounting OfficerMay 18 '26Sale5.087,89440,102107,057May 20
Xynos KonstantinosChief Medical OfficerMay 18 '26Sale5.0814,02371,237235,662May 20
Sarchi ChristopherChief Commercial OfficerApr 02 '26Sale8.016,50052,065151,588Apr 06
Dhingra KapilDirectorDec 09 '25Option Exercise1.753,1695,5463,169Dec 11
Dhingra KapilDirectorDec 09 '25Sale10.403,16932,9580Dec 11
Patel SushilChief Executive OfficerDec 02 '25Sale11.1310,000111,300333,576Dec 04
Sarchi ChristopherChief Commercial OfficerNov 17 '25Sale9.105,20847,393123,088Nov 19
Xynos KonstantinosChief Medical OfficerNov 17 '25Sale9.107,24865,957139,685Nov 19
Hill Emily LuisaChief Financial OfficerAug 15 '25Sale5.379,15449,157134,368Aug 19
Astley-Sparke PhilipDirectorMay 20 '25Sale8.0632,279260,1691,405,071May 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.